Briefly, there is a growing appreciation of the potential contributions of innate immune effectors to anti-tumor immunity and integrating a variety of means targeting adaptive immune system into PD-1/PD-L1 blockade based therapies could be a very important combination approach in future immunotherapy. The gene discussed is PDCD1; the disease is neoplasm.